Atyr Pharma Inc (NASDAQ: ATYR) on Friday, soared 10.39% from the previous trading day, before settling in for the closing price of $3.08. Within the past 52 weeks, ATYR’s price has moved between $1.42 and $4.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 545.22% over the past five years. The company achieved an average annual earnings per share of 3.09%. With a float of $81.24 million, this company’s outstanding shares have now reached $83.94 million.
Let’s look at the performance matrix of the company that is accounted for 59 employees. In terms of profitability, gross margin is -563.83%, operating margin of -28958.72%, and the pretax margin is -27155.32%.
Atyr Pharma Inc (ATYR) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Atyr Pharma Inc is 3.22%, while institutional ownership is 66.36%. The most recent insider transaction that took place on Feb 04 ’25, was worth 4,740. In this transaction Chief Financial Officer of this company sold 1,254 shares at a rate of $3.78, taking the stock ownership to the 31,763 shares. Before that another transaction happened on Feb 04 ’25, when Company’s General Counsel sold 899 for $3.78, making the entire transaction worth $3,398. This insider now owns 26,555 shares in total.
Atyr Pharma Inc (ATYR) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.29% during the next five years compared to 43.36% growth over the previous five years of trading.
Atyr Pharma Inc (NASDAQ: ATYR) Trading Performance Indicators
Atyr Pharma Inc (ATYR) is currently performing well based on its current performance indicators. A quick ratio of 5.41 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1240.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.94, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.85 in one year’s time.
Technical Analysis of Atyr Pharma Inc (ATYR)
Atyr Pharma Inc (NASDAQ: ATYR) saw its 5-day average volume 2.2 million, a positive change from its year-to-date volume of 1.23 million. As of the previous 9 days, the stock’s Stochastic %D was 31.11%. Additionally, its Average True Range was 0.36.
During the past 100 days, Atyr Pharma Inc’s (ATYR) raw stochastic average was set at 50.59%, which indicates a significant increase from 35.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 130.08% in the past 14 days, which was higher than the 85.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.67, while its 200-day Moving Average is $2.61. Nevertheless, the first resistance level for the watch stands at $3.66 in the near term. At $3.92, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.11. If the price goes on to break the first support level at $3.21, it is likely to go to the next support level at $3.01. The third support level lies at $2.75 if the price breaches the second support level.
Atyr Pharma Inc (NASDAQ: ATYR) Key Stats
Market capitalization of the company is 285.40 million based on 83,942K outstanding shares. Right now, sales total 350 K and income totals -50,390 K. The company made 0 K in profit during its latest quarter, and -16,310 K in sales during its previous quarter.
